Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study.
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
16
06
2018
revised:
21
08
2018
accepted:
26
08
2018
pubmed:
19
11
2018
medline:
6
5
2020
entrez:
19
11
2018
Statut:
ppublish
Résumé
In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy. We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97). Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration. National Institute for Health Research UK.
Sections du résumé
BACKGROUND
In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
METHODS
We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T
FINDINGS
Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97).
INTERPRETATION
Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.
FUNDING
National Institute for Health Research UK.
Identifiants
pubmed: 30447969
pii: S1474-4422(18)30325-9
doi: 10.1016/S1474-4422(18)30325-9
pmc: PMC6291458
pii:
doi:
Substances chimiques
Aspartic Acid
30KYC7MIAI
N-acetylaspartate
997-55-7
Banques de données
ClinicalTrials.gov
['NCT01309711']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-45Subventions
Organisme : Department of Health
ID : HCS DRF-2014-05-013
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CDRF-2016-02-071
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR/CS/010/022
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR300118
Pays : United Kingdom
Investigateurs
Peter J Lally
(PJ)
Paolo Montaldo
(P)
Vânia Oliveira
(V)
Aung Soe
(A)
Ravi Swamy
(R)
Paul Bassett
(P)
Josephine Mendoza
(J)
Gaurav Atreja
(G)
Ujwal Kariholu
(U)
Santosh Pattnayak
(S)
Palaniappan Sashikumar
(P)
Helen Harizaj
(H)
Martin Mitchell
(M)
Vijayakumar Ganesh
(V)
Sundeeep Harigopal
(S)
Jennifer Dixon
(J)
Philip English
(P)
Paul Clarke
(P)
Priya Muthukumar
(P)
Prakash Satodia
(P)
Sarah Wayte
(S)
Laurence J Abernethy
(LJ)
Kiran Yajamanyam
(K)
Alan Bainbridge
(A)
David Price
(D)
Angela Huertas
(A)
David J Sharp
(DJ)
Vaneet Kalra
(V)
Sanjay Chawla
(S)
Seetha Shankaran
(S)
Sudhin Thayyil
(S)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Pediatrics. 1999 Jun;103(6 Pt 1):1263-71
pubmed: 10353940
Ann Neurol. 1992 Jan;31(1):14-21
pubmed: 1543346
Lancet. 2005 Mar 5-11;365(9462):891-900
pubmed: 15752534
Neurology. 2007 Nov 13;69(20):1942-52
pubmed: 17998486
Lancet Neurol. 2010 Jan;9(1):39-45
pubmed: 19896902
Pediatrics. 2010 Feb;125(2):e382-95
pubmed: 20083516
Arch Pediatr Adolesc Med. 2012 Jul 1;166(7):634-40
pubmed: 22751877
Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F398-404
pubmed: 23080477
Pediatrics. 2013 Jan;131(1):88-98
pubmed: 23248219
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003311
pubmed: 23440789
Neuroradiology. 2013 Aug;55(8):1017-1025
pubmed: 23703033
Radiology. 2014 Mar;270(3):658-79
pubmed: 24568703
Curr Pediatr Rev. 2014;10(1):28-36
pubmed: 25055861
Curr Pediatr Rev. 2014;10(1):37-47
pubmed: 25055862
JAMA. 2014 Dec 24-31;312(24):2629-39
pubmed: 25536254
BMJ Open. 2015 Sep 30;5(9):e008912
pubmed: 26423856
Lancet Neurol. 2016 Feb;15(2):145-153
pubmed: 26708675
Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F147-F152
pubmed: 27553589
J Perinatol. 2017 Jun;37(6):684-689
pubmed: 28252661
Dev Neurosci. 2017;39(1-4):36-48
pubmed: 28448965
Magn Reson Imaging. 2017 Oct;42:82-87
pubmed: 28619605
JAMA. 2017 Jul 4;318(1):57-67
pubmed: 28672318
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
Trials. 2017 Sep 18;18(1):432
pubmed: 28923118
Arch Dis Child Fetal Neonatal Ed. 2018 Jul;103(4):F388-F390
pubmed: 28942433
J Pediatr. 2018 Jan;192:22-32
pubmed: 29031859
JAMA. 2017 Oct 24;318(16):1550-1560
pubmed: 29067428
Neonatology. 2018;113(4):331-338
pubmed: 29514165
Clin Perinatol. 2018 Jun;45(2):241-255
pubmed: 29747886
Radiology. 2018 Sep;288(3):840-848
pubmed: 29893645